HTTIF (HighTide Therapeutics) Ending Cash Position: $33.00 Mil (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Ending Cash Position?

HighTide Therapeutics HTTIF 14 Ending Cash Position is $33.00 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $33.00 Mil.

HighTide Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 ($42.68 Mil) to Jun. 2025 ($26.81 Mil) but then increased from Jun. 2025 ($26.81 Mil) to Dec. 2025 ($33.00 Mil).

HighTide Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($85.18 Mil) to Dec. 2024 ($42.68 Mil) and declined from Dec. 2024 ($42.68 Mil) to Dec. 2025 ($33.00 Mil).

HighTide Therapeutics Ending Cash Position Related Terms

HighTide Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Ending Cash Position Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
120.15 39.17 85.18 42.68 33.00

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only 85.18 40.28 42.68 26.81 33.00
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

HighTide Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=44.12+-11.125
=33.00

HighTide Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=27.332+5.663
=33.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $33.00 Mil mean?
HighTide Therapeutics (HTTIF) has a Ending Cash Position of $33.00 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Ending Cash Position too high?
HighTide Therapeutics' current Ending Cash Position is $33.00 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Ending Cash Position compare to VRTX and REGN?
HighTide Therapeutics' Ending Cash Position of $33.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Ending Cash Position is $33.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Ending Cash Position of $33.00 Mil. The current Ending Cash Position is $33.00 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Ending Cash Position is $33.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price